PriceTargets.com logo

Pieris Pharmaceuticals - PIRS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$11.72 As of 04/26/2024 05:28 PM ET
▲ +0.12 (1.03%)

This chart shows the closing price for PIRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pieris Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PIRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PIRS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Pieris Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $11.72.

This chart shows the closing price for PIRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Pieris Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/21/2023William BlairDowngradeOutperform ➝ Market PerformLow
7/2/2021William BlairReiterated RatingBuyN/A
6/30/2021Jefferies Financial GroupBoost TargetBuy$480.00 ➝ $640.00Low
4/26/2021HC WainwrightReiterated RatingBuy$720.00High
3/30/2021HC WainwrightReiterated RatingBuy$720.00Medium
8/10/2020HC WainwrightReiterated RatingBuyLow
8/9/2020William BlairReiterated RatingOutperformHigh
7/23/2020HC WainwrightReiterated RatingBuyMedium
3/13/2020Robert W. BairdUpgradeNeutral ➝ Outperform$400.00High
1/27/2020HC WainwrightBoost TargetBuy$560.00 ➝ $720.00Low
11/11/2019William BlairReiterated RatingBuyHigh
11/11/2019HC WainwrightReiterated RatingBuy$560.00High
9/27/2019William BlairReiterated RatingBuyHigh
9/27/2019HC WainwrightReiterated RatingBuy$560.00High
8/16/2019William BlairReiterated RatingBuyHigh
8/1/2019HC WainwrightReiterated RatingBuy$560.00Low
7/30/2019Robert W. BairdDowngradeOutperform ➝ Neutral$400.00High
6/17/2019HC WainwrightSet TargetBuy$560.00Low
5/23/2019HC WainwrightSet TargetBuy$560.00High
5/13/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$400.00High
5/13/2019CowenReiterated RatingBuyHigh
5/10/2019HC WainwrightReiterated RatingBuy$400.00 ➝ $560.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Pieris Pharmaceuticals logo
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $11.72
Low: $11.50
High: $11.93

50 Day Range

MA: $13.84
Low: $11.60
High: $17.24

52 Week Range

Now: $11.72
Low: $10.89
High: $80.80

Volume

16,948 shs

Average Volume

9,586 shs

Market Capitalization

$14.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Pieris Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Pieris Pharmaceuticals in the last year: StockNews.com, and William Blair.
View the latest analyst ratings for PIRS.

What is the current price target for Pieris Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Pieris Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Pieris Pharmaceuticals in the next year.
View the latest price targets for PIRS.

What is the current consensus analyst rating for Pieris Pharmaceuticals?

Pieris Pharmaceuticals currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PIRS, but not buy more shares or sell existing shares.
View the latest ratings for PIRS.

What other companies compete with Pieris Pharmaceuticals?

Other companies that are similar to Pieris Pharmaceuticals include Deciphera Pharmaceuticals, Collegium Pharmaceutical, Gemini Therapeutics, AbCellera Biologics and Mirum Pharmaceuticals. Learn More about companies similar to Pieris Pharmaceuticals.

How do I contact Pieris Pharmaceuticals' investor relations team?

Pieris Pharmaceuticals' physical mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company's listed phone number is (857) 246-8998 and its investor relations email address is [email protected]. The official website for Pieris Pharmaceuticals is www.pieris.com. Learn More about contacing Pieris Pharmaceuticals investor relations.